PharmaCyte Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jan '25 Jan 31, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021	Apr '20 Apr 30, 2020	2015 - 2019
Net Income	20.25	0.33	-4.32	-4.24	-3.55	-3.83	Upgrade
Asset Writedown & Restructuring Costs	2	2	-	-	-	-	Upgrade
Loss (Gain) From Sale of Investments	-10.13	1.57	-	-	-	-	Upgrade
Stock-Based Compensation	0.41	0.67	0.65	0.11	0.44	1.22	Upgrade
Other Operating Activities	-14.99	-7.03	0.17	-	-0.08	-	Upgrade
Change in Accounts Payable	0	0.26	-0.24	0.03	-0.01	0.06	Upgrade
Change in Other Net Operating Assets	0.18	0.04	-0.05	-0.02	-0.13	0.2	Upgrade
Operating Cash Flow	-2.27	-2.15	-3.79	-4.12	-3.33	-2.34	Upgrade
Other Investing Activities	-	-5	-	-	-	-	Upgrade
Investing Cash Flow	-7	-5	-	-	-	-	Upgrade
Long-Term Debt Issued	-	-	-	-	-	0.08	Upgrade
Total Debt Issued	-	-	-	-	-	0.08	Upgrade
Long-Term Debt Repaid	-	-	-	-0.05	-0.06	-0.01	Upgrade
Total Debt Repaid	-	-	-	-0.05	-0.06	-0.01	Upgrade
Net Debt Issued (Repaid)	-	-	-	-0.05	-0.06	0.06	Upgrade
Issuance of Common Stock	-	0	0	87.36	4.7	2.66	Upgrade
Repurchase of Common Stock	-3.55	-28.2	-13.56	-	-	-	Upgrade
Financing Cash Flow	-35.55	-10.71	-13.56	87.31	4.64	2.73	Upgrade
Foreign Exchange Rate Adjustments	-0	-0	-0.01	0	0	-0.01	Upgrade
Net Cash Flow	-44.83	-17.86	-17.36	83.2	1.31	0.38	Upgrade
Cash Interest Paid	-	-	-	0	0	0	Upgrade
Cash Income Tax Paid	-	0	-	0	0	0	Upgrade
Levered Free Cash Flow	-3.36	-2.55	-3.52	-2.62	-1.97	-1.03	Upgrade
Unlevered Free Cash Flow	-3.36	-2.55	-3.52	-2.62	-1.97	-1.03	Upgrade
Change in Net Working Capital	0.96	-0.85	0.13	-0.01	0.15	-0.14	Upgrade

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q